Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373

By In The News
November 15, 2021 in The Headlines

Recommended Posts

In The News

Posted November 15, 2021

- Share

Posted November 15, 2021

SK bioscience submits application for NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for BLA, to South Korea's MFDS GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  222599
2. Jaydee
  18134
3. deicer
  13663
4. Kip Powick
  12353
5. dagger
  9615
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  273k
- Total Posts
  
  566.6k

Sign In

Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support